SMARCA4 and familial pancreatic carcinoma: For example, according to the Atlas database, the rates of total mutations for BRG1 in melanoma, pancreatic cancer, and head/neck cancer are 7.83, 7.69, and 5.88%, respectively, but the rate of abrogating mutations is <0.3, 1.1, and 0.33%, respectively (Table 2A); in comparison, the loss of BRG1 by IHC in these two tumors is far higher, ~10–27, ~10–25, and ~18%, respectively (98–100) (Marquez et.al.